Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

7.47
-0.2400-3.11%
Post-market: 7.38-0.0900-1.20%19:24 EST
Volume:1.29M
Turnover:9.71M
Market Cap:1.04B
PE:-2.06
High:7.89
Open:7.79
Low:7.38
Close:7.71
52wk High:10.01
52wk Low:4.16
Shares:139.13M
Float Shares:94.55M
Volume Ratio:0.82
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6228
EPS(LYR):-3.8310
ROE:-49.06%
ROA:-25.97%
PB:1.31
PE(LYR):-1.95

Loading ...

Vir Biotechnology Inc. to Host Conference Call on Financial Results

Reuters
·
Feb 10

Vir Biotechnology Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
Feb 09

Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)

TIPRANKS
·
Feb 04

Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares

Reuters
·
Feb 04

Vir Biotechnology Reports Positive Data in Chronic Hepatitis Delta Trial

MT Newswires Live
·
Jan 14

H.C. Wainwright says Vir’s SOLSTICE 96-week data reinforces best-in-class

TIPRANKS
·
Jan 13

Vir Biotechnology updates on chronic hepatitis delta and oncology programs

TIPRANKS
·
Jan 13

BRIEF-Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones

Reuters
·
Jan 12

Vir Biotechnology Reports 88% Undetectable HDV RNA at 96 Weeks with Tobevibart and Elebsiran Combination Therapy

Reuters
·
Jan 12

Vir Biotechnology Inc: Positive, Updated Phase 2 Solstice Data Showed Combination of Tobevibart and Elebsiran Is Well Tolerated

THOMSON REUTERS
·
Jan 12

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

THOMSON REUTERS
·
Jan 12

Vir Biotechnology CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

Vir Biotechnology Director Vicki L. Sato Reports Disposal of Common Shares

Reuters
·
Jan 06

Vir Biotechnology Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 30, 2025

Pliant Therapeutics Appoints Minnie Kuo as Chief Operating Officer

Reuters
·
Dec 17, 2025

Vir Biotechnology Grants Norgine Exclusive License for Hepatitis Delta Treatment in Europe, Australia, and New Zealand

Reuters
·
Dec 17, 2025

Vir Biotechnology Inc - Norgine to Contribute 25% of Eclipse Program Costs

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology- Expects Current Cash, Cash Equivalents and Investments Will Be Extended Into Q4 2027

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing Eclipse Clinical Development Program

THOMSON REUTERS
·
Dec 17, 2025

Vir Biotechnology - to Receive EUR 55 Mln Initial Reimbursement Payment Upon Closing , EUR 495 Mln in Clinical, Regulatory and Sales Milestones

THOMSON REUTERS
·
Dec 17, 2025